Drug Profile

Research programme: anti-fibrotics - Takeda

Alternative Names: FT-01; FT-026; FT-061; FT-071; SHP-628; Tranilast analogues - Takeda

Latest Information Update: 15 Jan 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Fibrotech Therapeutics; University of Melbourne
Developer Shire
Class Anthranilic acids; Halogenated hydrocarbons; Small molecules
Mechanism of Action Collagen inhibitors; Platelet-derived growth factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

No development reported Arthritis; Chronic heart failure; Kidney disorders; Pulmonary fibrosis

08 Jan 2019 Shire has been acquired and merged into Takeda
28 Jul 2018 No recent reports of development identified for preclinical development in Arthritis in Australia
28 Jul 2018 No recent reports of development identified for preclinical development in Chronic-heart-failure in Australia

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com